<p>細胞動力（NASDAQ:CYTK - 獲取免費報告）於週四公佈了季度財報。這家生物製藥公司報告本季度每股收益為（$1.12），超出分析師一致預期的（$1.34）$0.22，Zacks 報道。該公司本季度的收入為 6677 萬美元，而一致預期為 195 萬美元。去年同期，該公司的每股收益為（$1.31）。與去年同期相比，該公司的季度收入增長了 26727.3%。</p>
<h2>細胞動力價格表現</h2>
<ul>
<li>分析師認為現在仍然有機會投資 Edgewise，股價上漲 332%</li>
</ul>
<p>NASDAQ:CYTK 在週五的交易時段下跌了$1.14，報$34.11。該公司交易了 2,104,845 股，較其平均交易量 1,250,101 股有所增加。該公司的市值為 40.7 億美元，市盈率為-6.69，貝塔值為 0.64。細胞動力的 52 周低點為$29.31，52 周高點為$59.39。該公司的 50 日移動平均價格為$34.88，200 日移動平均價格為$38.76。</p>
<h2>細胞動力內部交易活動</h2>
<p>在其他細胞動力的新聞中，董事 Edward M. Md Kaye 於 6 月 5 日星期四出售了 3,636 股公司的股票。股票以平均價格$32.10 出售，總交易額為$116,715.60。出售後，該董事持有 29,658 股公司的股票，估值約為$952,021.80。此次交易使其持股減少了 10.92%。該交易已在提交給證券交易委員會的文件中披露，文件可在此鏈接查看。此外，執行副總裁 Fady Ibraham Malik 於 8 月 5 日星期二出售了 2,000 股公司的股票。股票以平均價格$36.34 出售，總交易額為$72,680.00。出售後，該執行副總裁直接持有公司 140,610 股，估值約為$5,109,767.40。這代表其持股減少了 1.40%。該銷售的披露信息可在此處找到。過去 90 天內，內部人士已出售 39,749 股公司股票，價值$1,350,617。內部人士持有 2.70% 的股票。</p>
<h2>細胞動力的機構交易</h2>
<ul>
<li>想要在生物技術領域獲得多元化的上行潛力？查看 LABU</li>
</ul>
<p>一家對沖基金最近增加了對細胞動力股票的持股。Cetera Investment Advisers 在第二季度將其在細胞動力公司的股份提高了 12.4%，根據該公司最近向證券交易委員會提交的 13F 文件。該公司在此期間增持了 731 股，持有 6,635 股生物製藥公司的股票。Cetera Investment Advisers 在細胞動力的持股在最近一個季度末價值為$219,000。</p>
<h2>分析師評級變動</h2>
<p>多家券商最近對 CYTK 進行了評估。Raymond James Financial 於 7 月 30 日星期三開始覆蓋細胞動力的股票。他們對該公司設定了 “市場表現” 評級。瑞穗證券將細胞動力的目標價格從$103.00 下調至$84.00，並在 5 月 29 日星期四的研究報告中對該股票設定了 “跑贏大盤” 評級。花旗集團將細胞動力的目標價格從$80.00 下調至$77.00，並在週五的研究報告中對該股票設定了 “買入” 評級。瑞銀集團將細胞動力的目標價格從$47.00 下調至$41.00，並在 5 月 2 日星期五的研究報告中對該股票設定了 “中性” 評級。最後，美國銀行將細胞動力的目標價格從$62.00 下調至$54.00，並在 4 月 15 日星期二的研究報告中對該股票設定了 “中性” 評級。四位股票研究分析師對該股票給予了持有評級，十位給予了買入評級，兩位給予了強烈買入評級。根據 MarketBeat.com 的數據，該股票的共識評級為 “適度買入”，平均目標價格為$70.69。</p>
<p><strong>閲讀我們對細胞動力的最新分析</strong></p>
<h2>關於細胞動力</h2>
<p>（獲取免費報告）</p>
<p>細胞動力公司是一家處於後期階段的生物製藥公司，專注於發現、開發和商業化肌肉激活劑和抑制劑，作為潛在的治療虛弱疾病的方案。該公司主要開發小分子藥物候選者，旨在影響肌肉功能和收縮性。</p>
<h2>推薦故事</h2>
<ul>
<li>我們更看好的五隻股票超過細胞動力</li>
<li>CD 計算器：定期存款計算器</li>
<li>Rocket Lab 報告第二季度業績：牛市論點是否仍然成立？</li>
<li>投資於高市盈率成長股</li>
<li>特朗普 GLP-1 試點計劃可能推動諾和諾德和禮來</li>
<li>道瓊斯策略是什麼？概述和示例</li>
<li>現在是購買 Cheniere Energy 的好時機：預計將創下新高</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1lUSw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1lUSw"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在細胞動力嗎？</h2>
<p>在考慮細胞動力之前，你會想聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而細胞動力並不在名單上。</p>
<p>雖然細胞動力目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

細胞動力

<p>細胞動力（NASDAQ:CYTK）報告季度每股收益為（$1.12），超出預期的（$1.34）$0.22。公司實現收入 6677 萬美元，顯著超過 195 萬美元的預測，同比增長 26727.3%。股票交易下跌至 34.11 美元，市值為 40.7 億美元。內部交易活動包括董事 Edward M. Md Kaye 和執行副總裁 Fady Ibraham Malik 的銷售。分析師評級顯示共識為 “適度買入”，平均目標價為 70.69 美元</p>

<p>Cytokinetics (NASDAQ:CYTK - Get Free Report) announced its quarterly earnings data on Thursday. The biopharmaceutical company reported ($1.12) earnings per share for the quarter, beating analysts' consensus estimates of ($1.34) by $0.22, Zacks reports. The company had revenue of $66.77 million for the quarter, compared to the consensus estimate of $1.95 million. During the same quarter in the previous year, the business earned ($1.31) EPS. The company's quarterly revenue was up 26727.3% compared to the same quarter last year.</p>
<div class="lb-trans"><p>細胞動力（NASDAQ:CYTK - 獲取免費報告）於週四公佈了季度財報。這家生物製藥公司報告本季度每股收益為（$1.12），超出分析師一致預期的（$1.34）$0.22，Zacks 報道。該公司本季度的收入為 6677 萬美元，而一致預期為 195 萬美元。去年同期，該公司的每股收益為（$1.31）。與去年同期相比，該公司的季度收入增長了 26727.3%。</p>
</div><h2>Cytokinetics Price Performance</h2>
<div class="lb-trans"><h2>細胞動力價格表現</h2>
</div><ul>
<li>Analysts Think There's Still Time to Get in on Edgewise, Up 332%</li>
</ul>
<div class="lb-trans"><ul>
<li>分析師認為現在仍然有機會投資 Edgewise，股價上漲 332%</li>
</ul>
</div><p>NASDAQ:CYTK traded down $1.14 during trading hours on Friday, hitting $34.11. 2,104,845 shares of the company were exchanged, compared to its average volume of 1,250,101. The stock has a market capitalization of $4.07 billion, a price-to-earnings ratio of -6.69 and a beta of 0.64. Cytokinetics has a 52-week low of $29.31 and a 52-week high of $59.39. The company's 50 day moving average price is $34.88 and its 200-day moving average price is $38.76.</p>
<div class="lb-trans"><p>NASDAQ:CYTK 在週五的交易時段下跌了$1.14，報$34.11。該公司交易了 2,104,845 股，較其平均交易量 1,250,101 股有所增加。該公司的市值為 40.7 億美元，市盈率為-6.69，貝塔值為 0.64。細胞動力的 52 周低點為$29.31，52 周高點為$59.39。該公司的 50 日移動平均價格為$34.88，200 日移動平均價格為$38.76。</p>
</div><h2>Insider Activity at Cytokinetics</h2>
<div class="lb-trans"><h2>細胞動力內部交易活動</h2>
</div><p>In other Cytokinetics news, Director Edward M. Md Kaye sold 3,636 shares of the business's stock in a transaction that occurred on Thursday, June 5th. The shares were sold at an average price of $32.10, for a total transaction of $116,715.60. Following the sale, the director owned 29,658 shares of the company's stock, valued at approximately $952,021.80. The trade was a 10.92% decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this link. Also, EVP Fady Ibraham Malik sold 2,000 shares of the business's stock in a transaction that occurred on Tuesday, August 5th. The stock was sold at an average price of $36.34, for a total transaction of $72,680.00. Following the sale, the executive vice president directly owned 140,610 shares in the company, valued at approximately $5,109,767.40. This represents a 1.40% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 39,749 shares of company stock worth $1,350,617 in the last 90 days. 2.70% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在其他細胞動力的新聞中，董事 Edward M. Md Kaye 於 6 月 5 日星期四出售了 3,636 股公司的股票。股票以平均價格$32.10 出售，總交易額為$116,715.60。出售後，該董事持有 29,658 股公司的股票，估值約為$952,021.80。此次交易使其持股減少了 10.92%。該交易已在提交給證券交易委員會的文件中披露，文件可在此鏈接查看。此外，執行副總裁 Fady Ibraham Malik 於 8 月 5 日星期二出售了 2,000 股公司的股票。股票以平均價格$36.34 出售，總交易額為$72,680.00。出售後，該執行副總裁直接持有公司 140,610 股，估值約為$5,109,767.40。這代表其持股減少了 1.40%。該銷售的披露信息可在此處找到。過去 90 天內，內部人士已出售 39,749 股公司股票，價值$1,350,617。內部人士持有 2.70% 的股票。</p>
</div><h2>Institutional Trading of Cytokinetics</h2>
<div class="lb-trans"><h2>細胞動力的機構交易</h2>
</div><ul>
<li>Want Diversified Upside in Biotechnology? Check out LABU</li>
</ul>
<div class="lb-trans"><ul>
<li>想要在生物技術領域獲得多元化的上行潛力？查看 LABU</li>
</ul>
</div><p>A hedge fund recently raised its stake in Cytokinetics stock. Cetera Investment Advisers raised its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 12.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 6,635 shares of the biopharmaceutical company's stock after acquiring an additional 731 shares during the period. Cetera Investment Advisers' holdings in Cytokinetics were worth $219,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>一家對沖基金最近增加了對細胞動力股票的持股。Cetera Investment Advisers 在第二季度將其在細胞動力公司的股份提高了 12.4%，根據該公司最近向證券交易委員會提交的 13F 文件。該公司在此期間增持了 731 股，持有 6,635 股生物製藥公司的股票。Cetera Investment Advisers 在細胞動力的持股在最近一個季度末價值為$219,000。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><p>A number of brokerages recently weighed in on CYTK. Raymond James Financial began coverage on shares of Cytokinetics in a report on Wednesday, July 30th. They set a &#34;market perform&#34; rating for the company. Mizuho cut their target price on shares of Cytokinetics from $103.00 to $84.00 and set an &#34;outperform&#34; rating on the stock in a research report on Thursday, May 29th. Citigroup cut their target price on shares of Cytokinetics from $80.00 to $77.00 and set a &#34;buy&#34; rating on the stock in a research report on Friday. UBS Group cut their target price on shares of Cytokinetics from $47.00 to $41.00 and set a &#34;neutral&#34; rating on the stock in a research report on Friday, May 2nd. Finally, Bank of America cut their target price on shares of Cytokinetics from $62.00 to $54.00 and set a &#34;neutral&#34; rating on the stock in a research report on Tuesday, April 15th. Four equities research analysts have rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $70.69.</p>
<div class="lb-trans"><p>多家券商最近對 CYTK 進行了評估。Raymond James Financial 於 7 月 30 日星期三開始覆蓋細胞動力的股票。他們對該公司設定了 “市場表現” 評級。瑞穗證券將細胞動力的目標價格從$103.00 下調至$84.00，並在 5 月 29 日星期四的研究報告中對該股票設定了 “跑贏大盤” 評級。花旗集團將細胞動力的目標價格從$80.00 下調至$77.00，並在週五的研究報告中對該股票設定了 “買入” 評級。瑞銀集團將細胞動力的目標價格從$47.00 下調至$41.00，並在 5 月 2 日星期五的研究報告中對該股票設定了 “中性” 評級。最後，美國銀行將細胞動力的目標價格從$62.00 下調至$54.00，並在 4 月 15 日星期二的研究報告中對該股票設定了 “中性” 評級。四位股票研究分析師對該股票給予了持有評級，十位給予了買入評級，兩位給予了強烈買入評級。根據 MarketBeat.com 的數據，該股票的共識評級為 “適度買入”，平均目標價格為$70.69。</p>
</div><p><strong>Read Our Latest Analysis on Cytokinetics</strong></p>
<div class="lb-trans"><p><strong>閲讀我們對細胞動力的最新分析</strong></p>
</div><h2>About Cytokinetics</h2>
<div class="lb-trans"><h2>關於細胞動力</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.</p>
<div class="lb-trans"><p>細胞動力公司是一家處於後期階段的生物製藥公司，專注於發現、開發和商業化肌肉激活劑和抑制劑，作為潛在的治療虛弱疾病的方案。該公司主要開發小分子藥物候選者，旨在影響肌肉功能和收縮性。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than Cytokinetics</li>
<li>CD Calculator: Certificate of Deposit Calculator</li>
<li>Rocket Lab Reports Q2 Results: Is the Bull Thesis Still Intact?</li>
<li>Investing in the High PE Growth Stocks</li>
<li>Trump GLP-1 Pilot Program Could Boost Novo Nordisk &amp; Eli Lilly</li>
<li>What is the Dogs of the Dow Strategy? Overview and Examples</li>
<li>Now Is a Great Time to Buy Cheniere Energy: New High Expected</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票超過細胞動力</li>
<li>CD 計算器：定期存款計算器</li>
<li>Rocket Lab 報告第二季度業績：牛市論點是否仍然成立？</li>
<li>投資於高市盈率成長股</li>
<li>特朗普 GLP-1 試點計劃可能推動諾和諾德和禮來</li>
<li>道瓊斯策略是什麼？概述和示例</li>
<li>現在是購買 Cheniere Energy 的好時機：預計將創下新高</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1lUSw" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=CYTK"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Cytokinetics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在細胞動力嗎？</h2>
</div><p>Before you consider Cytokinetics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮細胞動力之前，你會想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cytokinetics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而細胞動力並不在名單上。</p>
</div><p>While Cytokinetics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然細胞動力目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

細胞動力（NASDAQ:CYTK）公佈了財報結果，每股收益超出預期 0.22 美元